Antidépresseurs, sur le site cbip-vet.be - consulté le 11 novembre 2012
doi.org
dx.doi.org
David T. Wong, Jong S. Horng, Frank P. Bymaster, Kenneth L. Hauser et Bryan B. Molloy, « A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-Trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine », Life Sciences, vol. 15, no 3, , p. 471–9 (PMID4549929, DOI10.1016/0024-3205(74)90345-2)
(en) Langford KH, Thomas KV. « Determination of pharmaceutical compounds in hospital effluents and their contribution to wastewater treatment works » Environ Int. 2009;35(5):769. PMID19336268DOI10.1016/j.envint.2009.02.007
(en) De Andrès F, Castañeda G, Rios A. « Use of Toxicity Assays for Enantiomeric Discrimination of Pharmaceutical Substances » Chirality 2009;21:751-758. PMID18989896DOI10.1002/chir.20675
Enagnon Kazali Alidjinou, Famara Sané, Antoine Bertin et Delphine Caloone, « Persistent infection of human pancreatic cells with Coxsackievirus B4 is cured by fluoxetine », Antiviral Research, vol. 116, , p. 51–54 (ISSN1872-9096, PMID25655448, DOI10.1016/j.antiviral.2015.01.010, lire en ligne, consulté le )
Kung-Chia Young, Chyi-Huey Bai, Hui-Chen Su et Pei-Ju Tsai, « Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways », Antiviral Research, vol. 110, , p. 158–167 (ISSN1872-9096, PMID25151487, DOI10.1016/j.antiviral.2014.08.002, lire en ligne, consulté le )
(en) Yi Xie, Pei-Pei Liu, Ya-Jun Lian et Hong-Bo Liu, « The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer’s disease and vascular dementia: focusing on fluoxetine with long follow-up periods », Signal Transduction and Targeted Therapy, vol. 4, no 1, , p. 1–3 (ISSN2059-3635, DOI10.1038/s41392-019-0064-7, lire en ligne, consulté le )
(en) Keun-A Chang, Jeong a Kim, Saeromi Kim et Yuyoung Joo, « Therapeutic potentials of neural stem cells treated with fluoxetine in Alzheimer’s disease », Neurochemistry International, honoring Nobel Laureate Dr. Marshall Nirenberg on Decoding Brain Memory, vol. 61, no 6, , p. 885–891 (ISSN0197-0186, DOI10.1016/j.neuint.2012.03.017, lire en ligne, consulté le )
(en) Jinping Qiao, Junhui Wang, Hongxing Wang et Yanbo Zhang, « Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model », Glia, vol. 64, no 2, , p. 240–254 (ISSN1098-1136, DOI10.1002/glia.22926, lire en ligne, consulté le )
Jeff Swiatek, « Prozac's profitable run coming to an end for Lilly », The Indianapolis Star, (lire en ligne)
issn.org
portal.issn.org
Enagnon Kazali Alidjinou, Famara Sané, Antoine Bertin et Delphine Caloone, « Persistent infection of human pancreatic cells with Coxsackievirus B4 is cured by fluoxetine », Antiviral Research, vol. 116, , p. 51–54 (ISSN1872-9096, PMID25655448, DOI10.1016/j.antiviral.2015.01.010, lire en ligne, consulté le )
Kung-Chia Young, Chyi-Huey Bai, Hui-Chen Su et Pei-Ju Tsai, « Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways », Antiviral Research, vol. 110, , p. 158–167 (ISSN1872-9096, PMID25151487, DOI10.1016/j.antiviral.2014.08.002, lire en ligne, consulté le )
(en) Yi Xie, Pei-Pei Liu, Ya-Jun Lian et Hong-Bo Liu, « The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer’s disease and vascular dementia: focusing on fluoxetine with long follow-up periods », Signal Transduction and Targeted Therapy, vol. 4, no 1, , p. 1–3 (ISSN2059-3635, DOI10.1038/s41392-019-0064-7, lire en ligne, consulté le )
(en) Keun-A Chang, Jeong a Kim, Saeromi Kim et Yuyoung Joo, « Therapeutic potentials of neural stem cells treated with fluoxetine in Alzheimer’s disease », Neurochemistry International, honoring Nobel Laureate Dr. Marshall Nirenberg on Decoding Brain Memory, vol. 61, no 6, , p. 885–891 (ISSN0197-0186, DOI10.1016/j.neuint.2012.03.017, lire en ligne, consulté le )
(en) Jinping Qiao, Junhui Wang, Hongxing Wang et Yanbo Zhang, « Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model », Glia, vol. 64, no 2, , p. 240–254 (ISSN1098-1136, DOI10.1002/glia.22926, lire en ligne, consulté le )
jfponline.com
Sutherland JE, Sutherland SJ, Hoehns JD, « Achieving the best outcome in treatment of depression », Journal of Family Practice, vol. 52, no 3, , p. 201–09 (PMID12620174, lire en ligne)
nature.com
(en) Yi Xie, Pei-Pei Liu, Ya-Jun Lian et Hong-Bo Liu, « The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer’s disease and vascular dementia: focusing on fluoxetine with long follow-up periods », Signal Transduction and Targeted Therapy, vol. 4, no 1, , p. 1–3 (ISSN2059-3635, DOI10.1038/s41392-019-0064-7, lire en ligne, consulté le )
newscientist.com
(en-US) « Antidepressant makes bones weaker by slowing down new growth », New Scientist, 10 semptember 2016, p. 14 (lire en ligne, consulté le )
nih.gov
ncbi.nlm.nih.gov
David T. Wong, Jong S. Horng, Frank P. Bymaster, Kenneth L. Hauser et Bryan B. Molloy, « A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-Trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine », Life Sciences, vol. 15, no 3, , p. 471–9 (PMID4549929, DOI10.1016/0024-3205(74)90345-2)
Sutherland JE, Sutherland SJ, Hoehns JD, « Achieving the best outcome in treatment of depression », Journal of Family Practice, vol. 52, no 3, , p. 201–09 (PMID12620174, lire en ligne)
(en) Langford KH, Thomas KV. « Determination of pharmaceutical compounds in hospital effluents and their contribution to wastewater treatment works » Environ Int. 2009;35(5):769. PMID19336268DOI10.1016/j.envint.2009.02.007
(en) Metcalfe CD, Miao XS, Koenig BG, Struger J. « Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada » Environ Toxicol Chem. 2003;22(12):2881–2889. PMID14713027
(en) De Andrès F, Castañeda G, Rios A. « Use of Toxicity Assays for Enantiomeric Discrimination of Pharmaceutical Substances » Chirality 2009;21:751-758. PMID18989896DOI10.1002/chir.20675
Enagnon Kazali Alidjinou, Famara Sané, Antoine Bertin et Delphine Caloone, « Persistent infection of human pancreatic cells with Coxsackievirus B4 is cured by fluoxetine », Antiviral Research, vol. 116, , p. 51–54 (ISSN1872-9096, PMID25655448, DOI10.1016/j.antiviral.2015.01.010, lire en ligne, consulté le )
Kung-Chia Young, Chyi-Huey Bai, Hui-Chen Su et Pei-Ju Tsai, « Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPARβ/γ-dependent pathways », Antiviral Research, vol. 110, , p. 158–167 (ISSN1872-9096, PMID25151487, DOI10.1016/j.antiviral.2014.08.002, lire en ligne, consulté le )
pmcpa.org.uk
(en) « Smithkline Beecham v Lilly -prozac advertisement », code of practice review, no 20, , p. 65-68 (lire en ligne)« active medicine might remain in the body for up to 3 months (5 times the half-life)(...) "true leadership has to be earned" "reducing the risk of discontinuation syndrome" prozac is rarely associated with unpleasant antidepressant discontinuation symptoms. Prozac's long half-life may protect against such symptoms. so Prozac makes it easy for you and your patients on stopping treatment or if therapy is interrupted". »
prescrire.org
(rédaction), « Façonner des maladies: l'empire du marketing », Rev Prescrire., vol. 27, no 283, , p. 381-382 (lire en ligne)
(en) Keun-A Chang, Jeong a Kim, Saeromi Kim et Yuyoung Joo, « Therapeutic potentials of neural stem cells treated with fluoxetine in Alzheimer’s disease », Neurochemistry International, honoring Nobel Laureate Dr. Marshall Nirenberg on Decoding Brain Memory, vol. 61, no 6, , p. 885–891 (ISSN0197-0186, DOI10.1016/j.neuint.2012.03.017, lire en ligne, consulté le )
(en) Janet C. Currie, Women and Health Protection (Organization), The Marketization of Depression: Prescribing SSRI Antidepressants to Women, Women and Health Protection, , 27 p. (ISBN0973870109, lire en ligne)« New disorders are often used to “reposition” an SSRI as it loses market share.(...)In
June 1999, when Prozac’s patent was about to expire, its manufacturer, Eli Lilly, organized a
roundtable of experts in the US to get PMDD approved – in order to extend Prozac’s patent life
under the name Serafem. According to Caplan, the creation of Serafem extended Lilly’s patent
on Prozac by seven years, thereby adding millions of dollars in profit. 78 Although the two drugs
were the same, Serafem was sold at a higher price than Prozac. »
(en) Jinping Qiao, Junhui Wang, Hongxing Wang et Yanbo Zhang, « Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model », Glia, vol. 64, no 2, , p. 240–254 (ISSN1098-1136, DOI10.1002/glia.22926, lire en ligne, consulté le )
